EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interleukin-27 in liver diseases: Pathological mechanisms and therapeutic targets

Yi-Fan Guo, Dong Ji

Hepatobiliary Communications · 2026

DOI: 10.1016/j.hbc.2026.100006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatobiliary Communications, 2026. Verfasst von Yi-Fan Guo und 1 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China, National Major Science and Technology Projects of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-27 (IL-27), generally regarded as a member of the interleukin-12 cytokine family, is a heterodimer composed of the p28 and EBI3 subunits. It signals through IL-27Ralpha/WSX-1 and gp130 to activate JAK-STAT pathways, especially STAT1 and STAT3. Beyond its indirect effects on T cells and NK cells, IL-27 can induce interferon-like antiviral and inflammatory programs in hepatocytes and mononuclear phagocytes, which helps explain its pleiotropic effects in liver disease. In hepatitis B virus (HBV) infection, IL-27 may support viral control by enhancing cytotoxic immunity and inducing antiviral states, but sustained intrahepatic IL-27 signaling may also be associated with T-cell dysfunction, immune regulation, and viral persistence. In hepatocellular carcinoma (HCC), IL-27 can promote antitumor immunity in selected immune compartments, whereas tumor-intrinsic or checkpoint-like IL-27/WSX-1 signaling may contribute to immune escape. Current evidence therefore supports a stage-specific, biomarker-guided, and compartment-aware interpretation of IL-27 biology rather than a uniformly protective or pathogenic model.

Förderung

  • Key Technologies Research and Development Program
  • National Natural Science Foundation of China
  • National Major Science and Technology Projects of China

Zitieren

APA

Guo, Y., & Ji, D. (2026). Interleukin-27 in liver diseases: Pathological mechanisms and therapeutic targets. Hepatobiliary Communications. https://doi.org/10.1016/j.hbc.2026.100006

Vancouver

Guo Y, Ji D. Interleukin-27 in liver diseases: Pathological mechanisms and therapeutic targets. Hepatobiliary Communications. 2026. doi:10.1016/j.hbc.2026.100006

BibTeX
@article{Guo2026,
  author = {Guo, Yi-Fan and Ji, Dong},
  title = {Interleukin-27 in liver diseases: Pathological mechanisms and therapeutic targets},
  journal = {Hepatobiliary Communications},
  year = {2026},
  doi = {10.1016/j.hbc.2026.100006}
}
Kostenlos starten →